Ethics of Pharma Clinical Trials in the Era of Precision Oncology

Area of Science:

• Oncology
• Clinical Trial Ethics
• Health Services Research

Background:

• Pharmaceutical industry clinical trials face ethical challenges, using human subjects primarily for regulatory approval.
• Randomized controlled trials (RCTs) can be inequitable, denying control groups access to potentially effective treatments.
• Many industry-sponsored trials lack demonstrable clinical benefits in overall survival and quality of life (QOL), limiting real-world applicability.

Purpose of the Study:

• To critically evaluate the ethical implications and limitations of current pharmaceutical industry clinical trials for anticancer agents.
• To propose an alternative, patient-centered approach utilizing real-world data (RWD) for evaluating novel cancer therapies.
• To explore how precision oncology and RWD can enhance ethical research and deliver meaningful patient benefits.

Main Methods:

• Analysis of ethical issues in pharmaceutical clinical trial design, particularly RCTs for oncology drugs.
• Discussion of the role of precision oncology in identifying eligible patient populations for targeted therapies.
• Proposal for a patient-centered research model leveraging prospective real-world data collection.

Main Results:

• Current trial designs often prioritize drug registration over patient well-being and generalizability.
• Precision oncology allows for targeted evaluation of molecularly-defined patient groups.
• Real-world evidence (RWE) from large populations can demonstrate cost-effective, sustained survival and QOL benefits.

Conclusions:

• Pharmaceutical trials require ethical reform to better serve patient interests and ensure clinical relevance.
• A shift towards patient-centered research using RWD is crucial for advancing oncology care.
• Integrating precision oncology with RWD collection can uphold the ethical doctor-patient relationship while generating robust evidence.